TOGETHER

Vyxeos is the first dual-drug advanced liposomal formulation of daunorubicin and cytarabine1

LONGER

Vyxeos is the first chemotherapy to significantly increase overall survival vs 7+3 in patients with high risk* AML2

TOGETHER

Vyxeos is the first dual-drug advanced liposomal formulation of daunorubicin and cytarabine1

LONGER

Vyxeos is the first chemotherapy to significantly increase overall survival vs 7+3 in patients with high risk* AML2

Vyxeos® is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).3

*High risk AML is defined as therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

References

  1. Tolcher AW, Mayer LD. Future Oncol 2018; 14(13):1317-32.
  2. Lancet JE et al. 2018. J Clin Oncol 2018. Published online ahead of print. doi: 10.1200/JCO.2017.77.6112
  3. VYXEOS Summary of product characteristics


ADVERSE EVENTS REPORTING

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. Adverse events should also be reported by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

EURW-INTVYX-0020a | September 2018